Metreleptin
An FDA-approved leptin analog used in rare metabolic disease, best known in the United States as Myalept.
Also referenced as: Myalept
This peptide maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Myalept
FDA label signal · 41 trials · 244 PubMed results
What metreleptin is
Metreleptin is a leptin analog marketed in the United States as Myalept.
Why it matters
It expands the library’s hormone and metabolic coverage beyond incretins and growth-related peptides into rare-disease endocrine therapeutics.
Regulatory context
Metreleptin is FDA approved in the United States for specific rare-disease use.
Practical reading note
Metreleptin is a good example of how a peptide can be clinically important without ever becoming a mainstream consumer-market name.